{"id":20647,"date":"2022-05-20T09:50:25","date_gmt":"2022-05-20T07:50:25","guid":{"rendered":"https:\/\/idibell.cat\/es\/?p=20647"},"modified":"2023-03-01T17:50:43","modified_gmt":"2023-03-01T16:50:43","slug":"nuevo-estudio-sobre-la-efectividad-de-dos-tratamientos-intravenosos-por-la-neuralgia-del-trigemino","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2022\/05\/nuevo-estudio-sobre-la-efectividad-de-dos-tratamientos-intravenosos-por-la-neuralgia-del-trigemino\/","title":{"rendered":"Nuevo estudio sobre la efectividad de dos tratamientos intravenosos por la neuralgia del trig\u00e9mino"},"content":{"rendered":"

La neuralgia del trig\u00e9mino es una afectaci\u00f3n que provoca una sensaci\u00f3n de dolor similar a una descarga el\u00e9ctrica en un lado de la cara. Esta sensaci\u00f3n est\u00e1 provocada por alteraciones del mismo nervio trig\u00e9mino que transmite la informaci\u00f3n desde la cara al cerebro.<\/p>\n

Existen varias opciones terap\u00e9uticas para este tipo de neuralgia, sin embargo, suelen tener efectos secundarios no deseados y el dolor reaparece en la mayor\u00eda de casos. Ahora el grupo de investigaci\u00f3n en Enfermedades Neurol\u00f3gicas y Neurogen\u00e9tica del IDIBELL y el Hospital Universitario de Bellvitge ha realizado un estudio para evaluar la efectividad y seguridad de dos f\u00e1rmacos intravenosos contra la neuralgia del trig\u00e9mino, la lacosamida y la fenito\u00edna<\/strong>. La v\u00eda intravenosa suele prevalecer en el tratamiento de las crisis agudas, puesto que aporta una mayor rapidez de acci\u00f3n y la administraci\u00f3n oral suele ser contraproducente debido al dolor.<\/p>\n

Los resultados del estudio publicados en Cephalalgia<\/em><\/a> demuestran que los dos f\u00e1rmacos son efectivos y seguros por el tratamiento agudo de la neuralgia del trig\u00e9mino. El estudio retrospectivo de 144 casos indica que m\u00e1s del 70% presentaba alivio del dolor con ambos f\u00e1rmacos<\/strong>. Sin embargo, el grupo de personas tratadas con lacosamida presentaban menos efectos adversos que el grupo tratado con fenito\u00edna, adem\u00e1s de mostrar una menor tasa de readmisi\u00f3n en el hospital y una mayor durabilidad del alivio.<\/p>\n

 <\/p>\n

 <\/p>\n

El Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL) es un centro de investigaci\u00f3n en biomedicina creado en 2004. Est\u00e1 participado por el Hospital Universitario de Bellvitge y el Hospital de Viladecans del Instituto Catal\u00e1n de la Salud, el Instituto Catal\u00e1n de Oncolog\u00eda, la Universidad de Barcelona y el Ayuntamiento de L’Hospitalet de Llobregat.<\/em><\/p>\n

El IDIBELL es miembro del Campus de Excelencia Internacional de la Universidad de Barcelona HUBc y forma parte de la instituci\u00f3n CERCA de la Generalitat de Catalunya. En 2009 se convirti\u00f3 en uno de los cinco primeros centros de investigaci\u00f3n espa\u00f1oles acreditados como instituto de investigaci\u00f3n sanitaria por el Instituto de Salud Carlos III. Adem\u00e1s, forma parte del programa \u00abHR Excellence in Research\u00bb de la Uni\u00f3n Europea y es miembro de EATRIS y REGIC. Desde el a\u00f1o 2018, IDIBELL es un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Un estudio retrospectivo del IDIBELL y el Hospital Universitario de Bellvitge con 144 casos muestra que el tratamiento intravenoso con lacosamida y fenito\u00edna es eficaz y seguro.<\/p>\n","protected":false},"author":8,"featured_media":20658,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[320,300,277],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-25 18:15:39","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/20647"}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=20647"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/20647\/revisions"}],"predecessor-version":[{"id":20648,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/20647\/revisions\/20648"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/20658"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=20647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=20647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=20647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}